[1]陈林,史丽君,陈姝,等.异基因造血干细胞移植联合供者CIK细胞过继免疫治疗复发难治血液肿瘤11例临床分析[J].第三军医大学学报,2012,34(24):2449-2452.
 Chen Lin,Shi Lijun,Chen Shu,et al.Allogeneic stem cell transplantation combined cytokine-induced-killer cells adaptive immunotherapy in treatment of refractory/relapsed hematologic neoplasms[J].J Third Mil Med Univ,2012,34(24):2449-2452.
点击复制

异基因造血干细胞移植联合供者CIK细胞过继免疫治疗复发难治血液肿瘤11例临床分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
34卷
期数:
2012年第24期
页码:
2449-2452
栏目:
论著
出版日期:
2012-12-30

文章信息/Info

Title:
Allogeneic stem cell transplantation combined cytokine-induced-killer cells adaptive immunotherapy in treatment of refractory/relapsed hematologic neoplasms
作者:
陈林史丽君陈姝邓建川周慷罗云张颖沈燕胡成琳娄世锋
重庆医科大学附属第二医院血液科
Author(s):
Chen Lin Shi Lijun Chen Shu Deng Jianchuan Zhou Kang Luo Yun Zhang Ying Shen Yan Hu Chenglin Lou Shifeng
Department of Hematology, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China
关键词:
造血干细胞移植肿瘤细胞因子诱导的杀伤细胞过继免疫细胞治疗
Keywords:
allogeneic stem cell transplantation cytokine-induced-killer cells adaptive immunotherapy
分类号:
R617;R730.51;R733
文献标志码:
A
摘要:
目的      观察异基因干细胞移植(allogeneic stem cell transplantation, allo-HSCT)联合供者细胞因子诱导的杀伤细胞(cytokine induced killer cells, CIK)过继免疫治疗复发难治血液肿瘤的效果。      方法      回顾性分析我科2005年3月至2012年3月行供者CIK细胞输注的allo-HSCT后复发难治血液肿瘤患者11例临床资料,其中急性髓系白血病3例,急性淋巴细胞白血病1例,慢性髓系白血病2例,多发性骨髓瘤1例,淋巴瘤4例。患者均进行亲缘allo-HSCT后给予供者CIK输注。      结果      移植后11例患者造血均重建,CIK细胞输注的中位次数为4(2~7)次,中位细胞总数为11.9×106/kg[(5.8~86.5)×106/kg];11例患者原发肿瘤均获完全缓解。4例移植后2~4个月再次复发(急性髓性白血病髓外复发1例,多发性骨髓瘤2例,慢粒急变1例),经供者CIK输注、停用免疫抑制剂后重获完全缓解3例。4例死亡,其中2例死于特发肺综合征,均为单倍型移植后原发肿瘤复发停用免疫抑制剂所致,另2例死于严重感染。总体中位生存时间9(2~53)个月;7例生存至今,生存时间12~53个月,除1例MM分子复发外,其余仍处于完全缓解。      结论      allo-HSCT联合供者CIK过继免疫治疗血液肿瘤有明显效果,副作用小,值得进一步进行多中心病例对照研究。
Abstract:
Objective      To evaluate the clinica1 efficacy of donor-derived cytokine induced killer cells (CIK) after allogeneic stem cell transplantation (allo-HSCT) in the treatment of patients with refractory/relapsed hematologic neoplasms.       Methods      Eleven refractory/relapsed patients, including acute myelogenous leukemia (AML) (n=3), acute lymphoblastic leukemia (ALL) (n=1), chronic myelomonocytic leukemia (CML) (n=2),  multiple myeloma (MM) (n=1) and non-Hodgkin lymphoma (NHL) (n=4), were enrolled in this retrospective analysis. All the patients accepted the infusions of donor-derived CIK after allo-HSCT.       Results      Hematopoietic reconstitution was achieved in 11 patients. The median number of CIK infusions was 4 (range 2 to 7) and the median number of total CIK cells was 11.9×106/kg (range 5.8 to 86.5). The primary disease achieved complete responses in all the patients. Four patient relapsed again after allo-HSCT and CIK cell infusion. However, 3 patients of them achieved complete responses after stopping immunosuppressive therapy and accepting the infusions of CIK. Among the 4 died patients, 2 died of idiopathic pulmonary syndrome, and 2 of severe infection. The median time of follow-up was 9 months (ranging from 2 to 53 months). During the follow-up period, 7 patients had always stayed CCR except 1 patient relapsed in molecule biology.       Conclusion      Allo-HSCT combined CIK adaptive immunotherapy is an effective therapy with little side effect for  minimal residual disease (MRD) clearance for malignancy, and it is worth of doing a multi-center controlled clinical trail study for its efficiency.

参考文献/References:

陈林, 史丽君,陈姝, 等. 异基因造血干细胞移植联合供者CIK细胞过继免疫治疗复发难治血液肿瘤11例临床分析[J]. 第三军医大学学报,2012,34(24):2449-2452.

相似文献/References:

[1]李艳莹,罗大先,陈惠,等.回生口服液对非小细胞肺癌患者凝血功能的影响[J].第三军医大学学报,2012,34(22):2259.
[2]张曦,张诚,陈幸华.重视造血干细胞移植中的造血微环境问题[J].第三军医大学学报,2012,34(24):2437.
 Zhang Xi,Zhang Cheng,Chen Xinghua.Pay close attention to hematopoietic inductive microenvironment in hematopoietic stem cell transplantation[J].J Third Mil Med Univ,2012,34(24):2437.
[3]李杰平,曾东风,孔祥敬,等.异基因造血干细胞移植治疗年轻慢性淋巴细胞白血病患者3例[J].第三军医大学学报,2012,34(24):2446.
 Li Jieping,Zeng Dongfeng,Kong Xiangjing,et al.Allogeneic hematopoietic stem cell transplantation in treatment of young chronic lymphocytic leukemia: report of 3 cases[J].J Third Mil Med Univ,2012,34(24):2446.
[4]李明,周永,糜漫天.染料木黄酮对人乳腺癌细胞株MDA-MB-453、MCF-7、MCF-7/HER2增殖能力的影响[J].第三军医大学学报,2008,30(17):1618.
 LI Ming,ZHOU Yong,MI Man-tian.Effect of genistein on proliferation of human breast cancer cell lines MDA-MB-453, MCF-7 and MCF-7/HER2[J].J Third Mil Med Univ,2008,30(24):1618.
[5]卞修武.对肿瘤研究前沿之肿瘤干细胞的几点认识[J].第三军医大学学报,2008,30(11):995.
[6]林爽,李力,易萍.低氧对宫颈癌HeLa细胞黏附及侵袭能力的影响[J].第三军医大学学报,2007,29(18):1776.
 LIN Shuang,LI Li,YI Ping.Effect of hypoxia on adhesion and invasion of human cervical cancer cell HeLa[J].J Third Mil Med Univ,2007,29(24):1776.
[7]王东.肿瘤分子病理和分子靶向治疗进展[J].第三军医大学学报,2006,28(02):91.
[8]王群波,蒋电明,李智,等.纳米羟基磷灰石/聚酰胺66复合人工椎体治疗胸腰椎椎体肿瘤的效果[J].第三军医大学学报,2006,28(03):263.
[9]余佩武,赵永亮.树突状细胞抗肿瘤作用研究进展[J].第三军医大学学报,2006,28(05):381.
[10]刘宿,蒋耀光,葛衡江,等.肺癌食管癌开胸手术患者术中凝血功能改变及其临床意义[J].第三军医大学学报,2007,29(09):779.
 LIU Su,JIANG Yao-guang,GE Heng-jiang,et al.Changes and clinical significance of coagulation function of patients with lung cancer or esophagus cancer in thoracotomy[J].J Third Mil Med Univ,2007,29(24):779.

更新日期/Last Update: 2012-12-19